Making eye contact Sep 22, 2009
The study results highlight the contacts' limits, including limited addition for near vision and correcting the effects of aging and eye diseases such as dry eye, astigmatism, cataract, glaucoma, etc. Pupil size is also a factor, Dampier said. (The Clarion-Ledger)
Color-blindness Cured by Gene Injection in Monkeys Sep 17, 2009
Calling the procedure his gene therapy "dream," researcher Jay Neitz said that "ultimately this could be a tool that could cure all sorts of eye diseases.". SHARE RELATED. (National Geographic)
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued Sep 12, 2009
ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's web site at. (PR Newswire)
Safety, efficacy of corneal transplant procedure confirmed; an antibiotic can cause double vision Sep 1, 2009
eye diseases and injuries, and perform eye surgery. To find an Eye M.D. in your area, visit the Academy's Web site at. (EurekAlert!)
Cambridge doctor receives merit award Sep 1, 2009
Since it was founded in 1960, RPB has channeled hundreds of millions of dollars to medical institutions for research into the causes, treatment and prevention of blinding eye diseases. For information on RPB, go to www. (Cambridge Chronicle, MA)
UM gets $20M gift to conduct research into autism Aug 28, 2009
Pericak-Vance said that his donation will bring more scientists and advanced equipment to the genetic institute, which researches cancer, eye diseases, Alzheimer s, autoimmune disorders, cardiovascular disease and Parkinson s.. John is a visionary with his outstanding contributions to the economy and science, Pericak-Vance said. (South Florida Business Journal, FL)
What you didn't know about the UM-St. Louis School of Optometry Aug 25, 2009
Eye health management is for patients with eye diseases including cataracts and glaucoma. The Center for Eye Care can also assist with contact lenses in addition to dispensing new frames. (The Current Online, MO)
Sanofi-Aventis could increase ophthalmology footprint with Allergan seen as strong candidate Aug 7, 2009
Bayer Healthcare, in turn, he said, has a notable partnership with Regeneron on the global development of VEGF Trap-Eye for the treatment of eye disease, including the neovascular form of wet age-related macular degeneration and diabetic eye diseases. The source close to the situation compared Sanofis M&A strategy to that of Bristol Myers Squibb (NYSE:BMY), which heralds a string of pearls strategy by acquiring companies in the EUR 2bn to EUR 5bn range. (FT.com -- Markets)
Anti-Growth Factor Drugs Raise Hope And Concern For Treatment Of Children's Eye Diseases Aug 4, 2009
3, 2009) A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus) ... However, at the much smaller doses used in eye diseases, the two antibodies appear to be safe ... Because of the urgent need for treatment of serious but relatively rare eye... (Science Daily)
Inspire's CEO to bow out Aug 2, 2009
Its nearly 250 workers are selling drugs to treat eye diseases such as pink eye and developing new medicines including a treatment for cystic fibrosis. Along the way, she developed a reputation as an advocate for Triangle nonprofits, businesses and entrepreneurs. (News & Observer)
R-Tech Ueno Notifies R&D Items Jul 31, 2009
Development code UF-021 (eye diseases) ... Development code RTU-007 (eye diseases) ... Development code RU-10 (eye diseases). (PR Newswire)
Otte awarded Doctor of Optometry degree Jul 28, 2009
Optometrists examine the internal and external structure of the eyes to diagnose eye diseases such as glaucoma, cataracts and retinal disorders; systemic diseases like hypertension and diabetes; and vision conditions like nearsightedness, farsightedness, astigmatism and presbyopia ... They prescribe eyeglasses and contact lenses, low vision aids, vision therapy and medications to treat eye diseases as well as perform certain surgical procedures. (Alva Review Courier, OK)
OXiGENE Announces Closing of Registered Direct Offering Jul 21, 2009
July 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: - ; Stockholm: - ), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has closed a registered direct offering of 6,250,000 units of its common stock and warrants as described below, at a price of $1 ... OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. (Primezone Releases)
Time to change our failed drug policies Jul 14, 2009
People who require cannabis (marijuana) as part of a medical regimen for various types of cancer and for certain eye diseases are being denied vital treatment. Illegal drugs are more readily available to young people today than many well-meaning people want to know. (Weymouth News, MA)
Fishing Trip Safety for Children Jul 12, 2009
Overexposure to ultraviolet rays makes kids more vulnerable to skin cancer, and eye diseases such as glaucoma and cataracts when they become adults. So to protect a child's delicate skin from the sun during fishing trips apply sunscreen liberally to exposed areas, and provide a wide brimmed hat and a pair of wraparound sunglasses to protect a youngster's face and eyes. (Suite101.com)
OXiGENE Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology Jul 6, 2009
July 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: - ; Stockholm: - ), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the Company exercised its option to acquire all of the equity of Symphony ViDA, Inc. in exchange for six million newly-issued shares of OXiGENE common stock, subject to adjustment as described below ... "The additional investment we're making in OXiGENE under this agreement reflects our continued... (Primezone Releases)
OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology Jun 25, 2009
" Clinicians and other medical professionals who would like more information about this study may contact OXiGENE at 650-635-7000. About PCV The choroid is the vascular layer at the back of the eye that lies between the retina and the sclera. In patients with PCV, dense clusters of polyp-like vascular structures, or polypoids, can be observed on the choroid with ICG angiography. Studies suggest that these polypoids may exist in up to one-third of wet AMD patients. The vascular phenotype of these... (Primezone Releases)
UTHSC shoots for stimulus Jun 23, 2009
They would study which genetic markers make a patient predisposed to certain types of eye diseases, which could make a breakthrough for personalized medicine. We re really trying to go to where the hockey puck is going to be, not where it was, Haik says. (Memphis Business Journal, TN)
OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer Jun 17, 2009
June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the appointment of Peter J. Langecker, M.D., Ph ... OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. (Primezone Releases)
Had Your Eyes Checked Lately? Jun 16, 2009
The problem with these perceptions is that most eye diseases come on subtly ... "They don't realize a lot of eye diseases don't have any symptoms in the early stages, which is where you'd like to treat those kinds of problems.". (MEDLINEplus)
Human Embryonic Stem Cells Could Safely Treat Eye Diseases, Research Suggests Jun 16, 2009
ScienceDaily (June 15, 2009) Advanced Cell Technology, Inc. and its collaborators at OHSU reported today the long-term safety and efficacy of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) produced under manufacturing conditions suitable for human clinical trials. Two important early potential hESC applications are the use of RPE for the treatment of age-related macular degeneration and Stargardt disease, an untreatable form of eye disease that leads to early-onset... (Science Daily)
Squid 'Sight' Sheds Light On Human Eye Diseases Jun 3, 2009
Not Just Through The Eyes: Squid 'Sight' Offers Insight Into Treating Human Eye Diseases ... Not Just Through The Eyes: Squid 'Sight' Offers Insight Into Treating Human Eye Diseases. (Science Daily)
OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting of the American Society of Clinical Oncology May 21, 2009
May 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that results from a Phase 2 clinical trial of its vascular disrupting agent (VDA) product candidate, ZYBRESTAT (fosbretabulin), in women with platinum-resistant ovarian cancer, will be presented in a symposium at the upcoming 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in... (Primezone Releases)
Saffron helps fight blindness May 18, 2009
SYDNEY: Saffron may help prevent loss of sight in old age and even improve vision in people suffering certain blinding eye diseases. Research by Silvia Bisti, professor at the ARC Centre of Excellence in Vision Science (The Vision Centre), University of L'Aquila, Italy, has established that saffron has remarkable effects on the genes which regulate the performance of the eye's key vision cells. (India Times, India)
Nutrition vital for good eyesight, studies show May 16, 2009
(ARA) - Caring for eyes includes paying attention to nutrition, with recent studies showing a strong correlation between good nutrition and the prevention of age-related eye diseases. Approximately 43 million Americans suffer from age-related macular degeneration or cataracts, the two leading causes of vision loss and blindness. (South County Chronicle, VA)
OXiGENE Announces First Quarter 2009 Earnings Conference Call and Webcast May 4, 2009
May 4, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report first quarter 2009 results on Monday, May 11, 2009 ... OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. (Primezone Releases)
Lower Dementia Drug Dose Boosts Brain Function, Cuts Side Effects Apr 30, 2009
3, 2005) The immunosuppressive drug mycophenolate mofetil, used to prevent rejection of transplanted hearts, kidneys and livers, may also be effective in controlling inflammatory eye diseases, according to a. (Oct. (Science Daily)
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion Apr 30, 2009
BERLIN and TARRYTOWN, N.Y., April 30 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: ) today announced that the companies are extending their global development program for VEGF Trap-Eye, an investigational agent for the treatment of certain eye diseases, to include Central Retinal Vein Occlusion (CRVO) ... Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, DME, CRVO, and other eye... (PR Newswire)
New Therapies Expected To Help Reduce Future Visual Burden Of Age-related Eye Disease Apr 20, 2009
13, 2004) With the aging of the population, the number of Americans with major eye diseases is increasing, and vision loss is becoming a major public health problem. By the year 2020, the number of people who. (Science Daily)
Two New Hereditary Corneal Disorders Discovered Apr 16, 2009
18, 2009) Extremely intense X-rays from Diamond - the UK's national synchrotron - are helping to advance research into the understanding and treatment of eye diseases. Due to the detailed nature of the. (Science Daily)
OXiGENE Begins Phase 1b/2a Trial of OXi4503, a Novel Second-Generation Vascular Disrupting Agent Apr 6, 2009
April 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the company has initiated a Phase 1b/2a study of its dual-mechanism, second-generation vascular disrupting agent (VDA), OXi4503, in patients with solid tumors with hepatic involvement ... OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. (Primezone Releases)
Experimental vaccine used in Ebola exposure case Mar 28, 2009
AP In this Oct. 2007 photo provided by the Hamburg University hospital (UKE) on March 17, 2009 a quarantine. By MELISSA EDDY and MIKE STOBBE, Associated Press Writers Melissa Eddy And Mike Stobbe, Associated Press Writers. (Yahoo News)
3-D Snapshots Of Eyes Reveal Details Of Age-related Blindness Mar 28, 2009
Optical coherence tomography (OCT) has become a standard tool for assessing AMD and other eye diseases. An OCT instrument shoots beams of infrared light into the retina, where they are reflected to greater or lesser extent by different structures within the eye. (Science Daily)
Roberta A. Pagon Receives Lifetime Award in Genetics from March of Dimes Mar 27, 2009
Her clinical work focuses on genetic eye diseases and syndrome delineation - reviewing the symptoms of patients who do not have a diagnosis to see if there might be a new disorder. "Dr. Pagon is responsible for sharing critical information about the diagnosis and management of genetic diseases with physicians worldwide," said Michael Katz, MD, March of Dimes senior vice president of Research and Global Programs, who will present the award today to Dr. Pagon at the Annual Clinical Genetics... (PR Newswire)
Genetic Sleuth Solves Glaucoma Mystery Mar 27, 2009
"Glaucoma is one of the few blinding eye diseases that we can actually treat. But right now we're only treating the symptoms, not the disease.". "If we can understand who gets glaucoma, then we're in a much better place to prevent it, and if we can understand why they get glaucoma, then we have some important clues to use in developing second-generation medications that treat the disease itself.". (Science Daily)
Allergan sweet spot for GSK as rumors abound of a possible bid Mar 26, 2009
The companys eye care drugs include prescription and nonprescription products to treat eye diseases and disorders, including glaucoma, dry eye, inflammation, allergy, and infection. On the dermatology front, the spokesperson was more sanguine. (FT.com -- Markets)
Screening Dogs For Inherited Health... Mar 25, 2009
Some of the more common tests are to detect heart disease, blood disorders, thyroid problems, hip dysplasia (dislocated hips, or HD), dwarfism, allergies, autoimmune problems, epilepsy and eye diseases such as progressive retinal atrophy (PRA) and inherited cataracts. What Clearances To Expect. (Suite101.com)
OXiGENE Reports Fourth Quarter and Year-End 2008 Results Mar 20, 2009
March 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and year ended December 31, 2008 ... OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. (Primezone Releases)
OXiGENE Announces Publication of Phase 2 Study Results With Fosbretabulin (ZYBRESTAT(tm)) Monotherapy in Anaplastic Thyroid Cancer (ATC) Mar 17, 2009
March 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the publication of results from a 26-patient, Phase 2 study of fosbretabulin (ZYBRESTAT) in anaplastic thyroid cancer (ATC) in the current issue of the journal THYROID. The authors of the study, titled ``A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of... (Primezone Releases)
Optometry students at Midwestern University to chart new course Mar 11, 2009
If that is not enough, the high count of Hispanics and Native Americans, who suffer disproportionately from eye diseases related to diabetes, will offer a ready-made audience for newly minted optometrists ... Optometrists are the primary eye doctors, trained to "detect, diagnose and manage visual dysfunctions and eye diseases," Santiago said. (AZCentral -- News)
Cats' Eye Diseases Genetically Linked To Diseases In Humans Mar 7, 2009
6, 2009) About one in 3,500 people are affected with retinitis pigmentosa (RP), a disease of the retina's visual cells that eventually leads to blindness. Now, a University of Missouri researcher has identified a genetic link between cats and humans for two different forms of RP. This discovery will help scientists develop gene-based therapies that will benefit both cats and humans. (Science Daily)
Easy ways to protect your eyes Mar 6, 2009
That's because UV rays can cause eye diseases, increased nearsightedness, and skin cancer around the eyes, says Alice Lyon, M.D., director of vitreoretinal service at Northwestern University Feinberg School of Medicine and ophthalmologist at Northwestern Memorial Hospital. Wear sunglasses anytime you're outdoors or driving (keep a spare pair in your car), even if it's overcast -- UV rays can do harm when it's cloudy, too. (CNN)
Screening For Vision Loss, Diabetic Retinopathy And Age-related Macular Degeneration, In The Blink Of An Eye Mar 1, 2009
28, 2009) In the blink of an eye, people at risk of becoming blind can now be screened for eye diseases such as diabetic retinopathy and age-related macular degeneration ... ORNL and UT researchers have created a better, quicker way to screen patients for eye diseases such as diabetic retinopathy and age-related macular degeneration. (Science Daily)
Canadians open door to learning-disorder drug Feb 24, 2009
Dr. McInnes, who specializes in genetic eye diseases, had been hunting genes involved in eye development in 2000 when he and his postdoctoral fellow David Ng came across the gene that makes Neto1. Eventually, research from his lab proved the protein to be very active in the brain particularly in sending messages between cells in the hippocampus, the seahorse-shaped brain region heavily involved in memory and learning. (Globe and Mail)
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis Feb 23, 2009
The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. (PR Newswire)
Oak Ridge technology can save vision Feb 19, 2009
WASHINGTON: People at risk of becoming blind can now be screened almost instantaneously for eye diseases like diabetic retinopathy and age-related macular degeneration. Macular degeneration is a condition usually affecting older adults which results in a loss of vision at the centre of the visual field (the macula) because of damage to the retina. (India Times, India -- Health/Science)
Working Toward Artificial Corneas Feb 19, 2009
18, 2009) Extremely intense X-rays from Diamond - the UK's national synchrotron - are helping to advance research into the understanding and treatment of eye diseases ... With around 65,000 penetrating corneal graft procedures being carried out worldwide each year2, this research is playing an important part in advancing eye surgery techniques that are vital to improving the quality of life of those affected by serious eye diseases and disorders. (Science Daily)
OXiGENE Announces Fourth Quarter and Fiscal 2008 Earnings Conference Call and Webcast Feb 19, 2009
Feb. 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (Stockholm: - ), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report fourth quarter and fiscal year-end 2008 results, along with guidance for 2009, on Thursday, February 26, 2009 ... OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. (Primezone Releases)
ORNL, UT project could save vision of millions Feb 18, 2009
Feb. 17, 2009 -- In the blink of an eye, people at risk of becoming blind can now be screened for eye diseases such as diabetic retinopathy and age-related macular degeneration. Using a technology originally developed at the Department of Energy's Oak Ridge National Laboratory to understand semiconductor defects, three locations in Memphis have been equipped with digital cameras that take pictures of the retina. (EurekAlert!)
UT tech-transfer program completes new round of project funding Feb 16, 2009
In addition, $25,000 was awarded through the Proof of Concept Roadrunner grant program to Andrew Tsin, professor in the Department of Biology at the University of Texas at San Antonio, for the construction of an instrument that can diagnose eye diseases, such as diabetic retinopathy and cancer. The $25,000 grant to the University of Texas at Brownsville went to Dr. Emilio Garrido, assistant professor in the Center for Biomedical Studies, for the development of therapeutic agents that can target... (San Antonio Business Journal, TX)
Visual Decline As We Age: Genetics Or Environment? Feb 12, 2009
Vision worsens for most of us as we age, even in the absence of eye diseases such as glaucoma or AMD. Elders who have good visual acuity (20/25 vision or better) may have trouble driving at night or adjusting when they move between indoor and outdoor light. Some declines are optic, such as presbyopia, reduced flexibility of the eye's lens, which causes poorer near vision for many people after age 40. (Science Daily)
Novartis/Nestle may see cycle of negotiations over Alcon option rights in 4Q 2009 Feb 11, 2009
Alcon develops prescription drugs for eye diseases such as glaucoma as well as allergy and non-steroid anti-inflammatory drugs, over-the-counter contact lens solutions, medical devices and products for ophthalmic surgery. Novartis currently has its own contact lens business, and along with Genentech, sells Lucentis for age-related macular degeneration. (FT.com -- Markets)
Team led by Scripps Scientists increases understanding of two types of blindness Feb 7, 2009
To better understand these eye diseases, and to develop new and better treatments, the research team examined a mouse model of these human diseases. The particular "knockout" mouse the team focused on has been used by other researchers for studying fat metabolism. (EurekAlert!)
Diabetic Eye Disease Rates Soaring Feb 7, 2009
"People with diabetes mellitus also have a higher prevalence of other eye diseases, such as cataracts and glaucoma, than the general population," the researchers wrote. "Vision loss related to eye disease among people with diabetes is an important disability that threatens independence and can lead to depression, reduced mobility and reduced quality of life.". (MEDLINEplus)
